Abstract
For more than 50 years, pharmacotherapy for major depressive disorder (MDD) has narrowly focused on enhancing monoaminergic neurotransmission resulting in more than 30 FDA- approved treatments. In contrast, the glutamatergic, non-competitive N-methyl D-aspartate (NMDA) receptor antagonist ketamine has been "repurposed" as a rapid acting antidepressant1 ; the enantiomer S-ketamine, or esketamine, is now FDA-approved for treatment resistant unipolar depression (TRD).
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call